Compare · ARGX vs CVM
ARGX vs CVM
Side-by-side comparison of argenx SE (ARGX) and Cel-Sci Corporation (CVM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and CVM operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.52B, about 1716.1x CVM ($30.6M).
- ARGX has been more active in the news (6 items in the past 4 weeks vs 3 for CVM).
- ARGX has more recent analyst coverage (25 ratings vs 0 for CVM).
- Company
- argenx SE
- Cel-Sci Corporation
- Price
- -
- -
- Market cap
- $52.52B
- $30.6M
- 1M return
- -
- +15.03%
- 1Y return
- -
- -80.21%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 2017
- 1997
- News (4w)
- 6
- 3
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Cel-Sci Corporation
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest CVM
- Chief Scientific Officer Talor Eyal was granted 1,165 shares, increasing direct ownership by 13% to 10,483 units (SEC Form 4)
- Chief Financial Officer Prichep Patricia B was granted 2,082 shares, increasing direct ownership by 12% to 19,571 units (SEC Form 4)
- Chief Executive Officer Kersten Geert R was granted 2,621 shares, increasing direct ownership by 0.83% to 318,763 units (SEC Form 4)
- CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
- SEC Form S-8 filed by Cel-Sci Corporation
- Chief Executive Officer Kersten Geert R bought $138,000 worth of shares (100,000 units at $1.38), increasing direct ownership by 46% to 316,142 units (SEC Form 4)
- SEC Form 4 filed by Director Watson Robert Eugene
- SEC Form 4 filed by Director Baillavoine Bruno Jean-Marie
- SEC Form 4 filed by Senior Vice President Cipriano John
- SEC Form 4 filed by Chief Scientific Officer Talor Eyal